WO2003029414A3 - INTRODUCTION OF THE WLDs GENE FOR PREVENTION OF AXONAL DEGENERATION IN NEUROLOGICAL DISEASES - Google Patents

INTRODUCTION OF THE WLDs GENE FOR PREVENTION OF AXONAL DEGENERATION IN NEUROLOGICAL DISEASES Download PDF

Info

Publication number
WO2003029414A3
WO2003029414A3 PCT/US2002/031078 US0231078W WO03029414A3 WO 2003029414 A3 WO2003029414 A3 WO 2003029414A3 US 0231078 W US0231078 W US 0231078W WO 03029414 A3 WO03029414 A3 WO 03029414A3
Authority
WO
WIPO (PCT)
Prior art keywords
wlds
gene
introduction
prevention
neurological diseases
Prior art date
Application number
PCT/US2002/031078
Other languages
French (fr)
Other versions
WO2003029414A2 (en
Inventor
Jonathan D Glass
Mark M Rich
Original Assignee
Univ Emory
Jonathan D Glass
Mark M Rich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory, Jonathan D Glass, Mark M Rich filed Critical Univ Emory
Priority to US10/433,035 priority Critical patent/US20040127439A1/en
Priority to EP02800391A priority patent/EP1446014A4/en
Priority to CA002462632A priority patent/CA2462632A1/en
Publication of WO2003029414A2 publication Critical patent/WO2003029414A2/en
Publication of WO2003029414A3 publication Critical patent/WO2003029414A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Polypeptides that can protect axons from axon degeneration and methods of use of the polypeptides are presented. Polynucleotides that can protect axons from axon degeneration and methods of use of the polynucleotides are presented. In addition, polynucleotides that encode the polypeptides referred to above are presented. Further, pharmaceutical compositions to treat conditions are presented.
PCT/US2002/031078 2001-10-01 2002-10-01 INTRODUCTION OF THE WLDs GENE FOR PREVENTION OF AXONAL DEGENERATION IN NEUROLOGICAL DISEASES WO2003029414A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/433,035 US20040127439A1 (en) 2002-10-01 2002-10-01 Introduction of the wld gene for prevention of axonal degeneration in neurological diseases
EP02800391A EP1446014A4 (en) 2001-10-01 2002-10-01 INTRODUCTION OF THE WLDs GENE FOR PREVENTION OF AXONAL DEGENERATION IN NEUROLOGICAL DISEASES
CA002462632A CA2462632A1 (en) 2001-10-01 2002-10-01 Introduction of the wlds gene for prevention of axonal degeneration in neurological diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32635401P 2001-10-01 2001-10-01
US60/326,354 2001-10-01

Publications (2)

Publication Number Publication Date
WO2003029414A2 WO2003029414A2 (en) 2003-04-10
WO2003029414A3 true WO2003029414A3 (en) 2003-12-18

Family

ID=23271854

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/031078 WO2003029414A2 (en) 2001-10-01 2002-10-01 INTRODUCTION OF THE WLDs GENE FOR PREVENTION OF AXONAL DEGENERATION IN NEUROLOGICAL DISEASES

Country Status (3)

Country Link
EP (1) EP1446014A4 (en)
CA (1) CA2462632A1 (en)
WO (1) WO2003029414A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004028466A2 (en) * 2002-09-25 2004-04-08 Georiga Tech Research Corporation Ketoamide inhibitors in chronic nerve disease
GB201006961D0 (en) * 2010-04-27 2010-06-09 Babraham Inst NMN modulator
WO2019009979A1 (en) * 2017-07-06 2019-01-10 The Medical College Of Wisconsin, Inc. Novel in vitro and in vivo enrichment strategy targeting lymphocytes derived from vector transduced hscs for therapy of disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064907A2 (en) * 2000-03-02 2001-09-07 Incyte Genomics, Inc. Lipid metabolism enzymes

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CONFORTI ET AL.: "A Ufd2/D4Cole1e chimeric protein and overexpression of Rbp7 in the slow Wallerian degeneration (WldS) mouse", PROC. NATL. ACAD. SCI. USA, vol. 97, no. 21, 10 October 2000 (2000-10-10), pages 11377 - 11382, XP002953257 *
DATABASE GENBANK [online] 16 October 2000 (2000-10-16), "Mus musculus UFD2/D4COLE1E fusion protein mRNA", XP002953260, Database accession no. (AF260924) *
FERNANDO ET AL.: "Characterization of the human homologue of a candidate gene for slow Wallerian degeneration", AMERICAN JOURNAL OF HUMAN GENETICS, vol. 67, no. SUPPLEMENT 2, October 2000 (2000-10-01), pages 178, XP002953261 *
See also references of EP1446014A4 *
WANG ET AL.: "Pathogenesis of axonal degeneration: parallels between Wallerian degeneration and vincristine neuropathy", J. OF NEUROPATHOLOGY AND EXP. NEUROLOGY, vol. 59, no. 7, July 2000 (2000-07-01), pages 599 - 606, XP002953258 *
WANG ET AL.: "The gene for low Wallerian degeneration (WldS) is also protective against vincristine neuropathy", NEUROBIOLOGY OF DISEASE, vol. 8, 20 December 2000 (2000-12-20), pages 155 - 161, XP002953259 *

Also Published As

Publication number Publication date
EP1446014A4 (en) 2004-12-08
CA2462632A1 (en) 2003-04-10
WO2003029414A2 (en) 2003-04-10
EP1446014A2 (en) 2004-08-18

Similar Documents

Publication Publication Date Title
WO2002060317A3 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2002002624A3 (en) B7-like molecules and uses thereof
WO2001070977A3 (en) Fibroblast growth factor receptor-like molecules and uses thereof
EP1140840A4 (en) -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2002024891A3 (en) B7-like molecules and uses thereof
WO2002085857A3 (en) Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
WO2005004794A3 (en) Method of treating neurodegenerative disease
WO2000073469A3 (en) Protein kinases
WO2002089747A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002074156A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
WO2006060680A3 (en) Mda-7 protein variants having antiproliferative activity
WO2002092001A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001061007A3 (en) Fibroblast growth factor-23 molecules and uses thereof
WO2002074237A8 (en) Compositions and methods for the therapy and diagnosis of kidney cancer
WO2001079164A3 (en) N-substituted dithiocarbamates for the treatment of biological disorders
WO2001068854A3 (en) Fibroblast growth factor-like molecules and uses thereof
WO2000029846A3 (en) COMPOSITIONS AND METHODS RELATING TO THE PEROXISOMAL PROLIFERATOR ACTIVATED RECEPTOR-α MEDIATED PATHWAY
WO2003037267A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003024991A3 (en) Tall-1 receptor molecules and uses thereof
WO2001042474A3 (en) Interferon-like molecules and uses thereof
WO2003029414A3 (en) INTRODUCTION OF THE WLDs GENE FOR PREVENTION OF AXONAL DEGENERATION IN NEUROLOGICAL DISEASES
WO2001031008A3 (en) Human and rat fgf-20 genes and gene expression products
WO1999020291A3 (en) Pharmaceutical grade ginkgo biloba
WO2002097046A3 (en) B7 related protein-2 molecules and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG US

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10433035

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003532632

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2462632

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002362458

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002800391

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002800391

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002800391

Country of ref document: EP